Alexandria Company for Pharmaceuticals and Chemical Industries
EEGX:AXPH1,258.26
EGP
-44.89
(-3.44%)
ISIN
EGS38341C011
Return %
Stock
S&P 500
1Y
39.67
14.20
3Y
750.18
81.12
5Y
720.09
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Abla Youssef Abdullah
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Alexandria Egypt
- IPO Date
- Feb 27, 1995
- Similar Companies
- Business
- Alexandria Company for Pharmaceuticals and Chemical Industries S.A.E. is an Egypt-based pharmaceutical manufacturing enterprise engaged in the development, production, marketing, and distribution of human pharmaceuticals, veterinary drugs, dietary supplements, medical appliances, and specialized chemical products. Established in 1962 and headquartered in Alexandria, Egypt, the company operates as a subsidiary of the state-owned Holding Company for Pharmaceuticals, Chemicals and Medical Appliances (HoldiPharma) and trades publicly on the Egyptian Exchange under the ticker AXPH. The company manufactures a wide array of dosage forms and therapeutic formulations across dedicated production units, including solid dosage forms such as tablets, sugar-coated tablets, film-coated tablets, hard gelatin capsules, and sustained-release formulations; liquid oral dosage forms such as syrups, oral drops, and suspensions; sterile liquid injectables comprising ampoules, vials, and dental anesthetic cartridges; semi-solid topical formulations including creams, ointments, and dermatological gels; rectal suppositories; and dry powder effervescent granules and sachets. Its core therapeutic categories encompass cardiovascular and antihypertensive agents; broad-spectrum antibiotics, antifungals, and anti-infective medications; analgesics, antipyretics, and non-steroidal anti-inflammatory drugs; gastrointestinal, anti-ulcer, and antispasmodic treatments; respiratory, antihistaminic, and bronchodilator therapies; central nervous system agents; metabolic and endocrine regulators; vitamins, minerals, and dietary health supplements; veterinary anti-infectives and growth stimulants; and specialized oral healthcare solutions. Alexandria Company for Pharmaceuticals and Chemical Industries distributes its pharmaceutical portfolio across domestic public hospitals, private clinics, healthcare institutions, and commercial pharmacy networks throughout Egypt, while maintaining export operations to regional markets across the Middle East, Africa, and select Eastern European countries. In recent operational developments, the company has executed comprehensive modernization and upgrade initiatives across its sterile injectable and solid dosage manufacturing suites to align with current Good Manufacturing Practice (cGMP) and international regulatory standards. Furthermore, the company has expanded its toll and contract manufacturing partnerships with regional and multinational pharmaceutical developers, accelerated the registration and commercial rollout of generic medications targeting chronic therapeutic segments, and participated in Egyptian healthcare initiatives focused on localizing essential drug manufacturing and strengthening pharmaceutical raw material supply chains.